Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
630 stopped studies mapped to Malignant Hepatobiliary Neoplasm and descendants · 92% state a reason
Over the 630 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With… | Phase 1 / Phase 2 | terminated | Nov 10, 2008 | City of Hope Medical Center | Terminated early due a shift in resources after lackluster performance of the drug. | Other (stated, no rule matched) |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating… | Phase 1 / Phase 2 | withdrawn | Nov 5, 2021 | University of Rochester | no accrual of eligible participants | Enrollment / accrual |
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced…(DEDUCTIVE) | Phase 1 / Phase 2 | terminated | May 31, 2019 | AVEO Pharmaceuticals, Inc. | The study was terminated due to regulatory approval of newer therapeutic options and slower than… | Enrollment / accrual |
| NCT03722498 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | Phase 2 | withdrawn | Oct 29, 2018 | Sun Yat-sen University | No patients join | Other (stated, no rule matched) |
| NCT03591965 | Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular… | Phase 2 | terminated | Jul 19, 2018 | Antengene Therapeutics Limited | Based on the adjustment of clinical research and development strategy，sponsor decided to terminate… | Sponsor / business decision |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | Phase 2 | terminated | May 30, 2014 | QED Therapeutics, a BridgeBio company | The study was terminated early due to limited efficacy in Cohorts 2 and 3 (exploratory endpoints).… | Safety / toxicity |
| NCT00301379 | Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients | — | terminated | Mar 10, 2006 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT05564338 | Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus… | Phase 3 | withdrawn | Oct 3, 2022 | BeiGene | Study has voluntarily discontinued due to a change in the company-level development strategy and is… | Safety / toxicity |
| NCT05886257 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | Phase 2 | withdrawn | Jun 2, 2023 | Shi Ming | Protocol adjustment | Other (stated, no rule matched) |
| NCT05375604 | A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma… | Phase 1 | terminated | May 16, 2022 | Codiak BioSciences | Company Bankruptcy | Sponsor / business decision |
| NCT04163900 | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced… | Phase 3 | terminated | Nov 15, 2019 | NuCana plc | A pre-planned futility analysis concluded that NUC-1031 plus cisplatin was unlikely to achieve its… | Efficacy / futility |
| NCT05039736 | A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR… | Phase 2 | withdrawn | Sep 10, 2021 | M.D. Anderson Cancer Center | 0 participants accrued | Enrollment / accrual |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | Phase 4 | withdrawn | Jun 25, 2014 | Tokyo Medical and Dental University | I retired my post before enrollment | Enrollment / accrual |
| NCT03662841 | Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma | N/A | terminated | Sep 10, 2018 | Chinese University of Hong Kong | poor patient accrual | Enrollment / accrual |
| NCT03808766 | A Study on the Angioarchitecture of Hepatocellular Carcinoma | N/A | terminated | Jan 18, 2019 | Chinese University of Hong Kong | Poor patient accrual | Enrollment / accrual |
| NCT05249569 | Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Feb 21, 2022 | University of Texas Southwestern Medical Center | Sponsor pulled support for one of the study drugs. | Other (stated, no rule matched) |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected… | Phase 2 | withdrawn | Jun 27, 2019 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT03790111 | A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With…(TELE-ABC) | Phase 2 | terminated | Dec 31, 2018 | TerSera Therapeutics LLC | Did not meet pre-specified Progression-Free Survival at Month 6 for Stage 2 Analysis | Other (stated, no rule matched) |
| NCT04150874 | Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow… | Early Phase 1 | terminated | Nov 5, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Slow Accrual | Enrollment / accrual |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Phase 2 | terminated | Jun 22, 2020 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT00430313 | Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by… | N/A | withdrawn | Feb 1, 2007 | M.D. Anderson Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT04777708 | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | Early Phase 1 | terminated | Mar 2, 2021 | Jonsson Comprehensive Cancer Center | Withdrawn by sponsor | Other (stated, no rule matched) |
| NCT05157451 | Y-90 Versus SBRT for Inoperable HCC | Phase 2 | withdrawn | Dec 15, 2021 | OHSU Knight Cancer Institute | Not feasible at this time. | Other (stated, no rule matched) |
| NCT04635527 | A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE)… | Phase 1 | terminated | Nov 19, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue… | Sponsor / business decision |
| NCT04649671 | The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With… | N/A | terminated | Dec 2, 2020 | Samsung Medical Center | Difficulty in recruitment and deficit of research fund | Enrollment / accrual |
| NCT02899325 | FDGal PET/CT to Detect Hepatocellular Carcinoma | — | withdrawn | Sep 14, 2016 | British Columbia Cancer Agency | PIs will not pursue trial due to staff and time constraints | Other (stated, no rule matched) |
| NCT04965714 | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | Phase 2 | withdrawn | Jul 16, 2021 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT05592197 | Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT | N/A | withdrawn | Oct 24, 2022 | Sun Yat-sen University | This is a sub-study of another one. | Other (stated, no rule matched) |
| NCT03236649 | The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced… | Phase 3 | terminated | Aug 2, 2017 | Beijing Shenogen Biomedical Co., Ltd | Because the clinical development plan has been changed. | Other (stated, no rule matched) |
| NCT04784520 | A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer | Phase 2 | terminated | Mar 5, 2021 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The primary endpoint did not meet expectation. | Other (stated, no rule matched) |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT05628545 | Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | Phase 1 / Phase 2 | withdrawn | Nov 28, 2022 | Guangdong GD Kongming Biotech LLC | COVID1-19 pandemic | COVID-19 / pandemic |
| NCT03582618 | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Jul 11, 2018 | TaiRx, Inc. | The study has been terminated due to slow enrollment | Enrollment / accrual |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT01433016 | Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI(OBT for HCC) | Phase 2 | terminated | Sep 13, 2011 | Meridian Bioscience, Inc. | Due to budgetary issues, the company has decided to focus on other applications at this stage. | Funding |
| NCT01381211 | Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of…(TRACE) | Phase 2 | terminated | Jun 27, 2011 | University Hospital, Ghent | based on interim analysis results | Efficacy / futility |
| NCT03781960 | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | Phase 2 | terminated | Dec 20, 2018 | Abramson Cancer Center at Penn Medicine | Safety letter from sponsor | Safety / toxicity |
| NCT04178642 | The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion…(LIDA-ADJ) | Phase 2 | withdrawn | Nov 26, 2019 | University Hospital, Montpellier | no participants enrolled | Enrollment / accrual |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of… | Phase 2 | withdrawn | Apr 14, 2022 | OHSU Knight Cancer Institute | Due to inadequate funding. This trial may open as a new clinical trial at a later date, pending… | Funding |
| NCT04076761 | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma(MOCHA) | Phase 2 | terminated | Sep 3, 2019 | Sunnybrook Health Sciences Centre | Lack of Funding | Funding |
| NCT04304781 | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer | Phase 1 | terminated | Mar 11, 2020 | Danielle Kim Turgeon | Terminated due to lack of dimer. | Other (stated, no rule matched) |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell… | Phase 1 | withdrawn | Nov 23, 2020 | National Cancer Institute (NCI) | Safety issues with PI3 kinase inhibitors | Safety / toxicity |
| NCT01167374 | Carbon Ion Radiotherapy for Hepatocellular Carcinoma(PROMETHEUS-01) | N/A | terminated | Jul 22, 2010 | University Hospital Heidelberg | Slow recruitment rate | Enrollment / accrual |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With… | Phase 2 | terminated | Apr 14, 2015 | Delcath Systems Inc. | Limited enrollment | Enrollment / accrual |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced… | Phase 1 | terminated | Oct 26, 2021 | H. Lee Moffitt Cancer Center and Research Institute | Loss of funding | Funding |
| NCT04985136 | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice… | Phase 3 | terminated | Aug 2, 2021 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
| NCT03945799 | A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk… | Phase 1 / Phase 2 | terminated | May 10, 2019 | Zhejiang University | The study has gotten preliminary results and stopped advanced. | Other (stated, no rule matched) |
| NCT03353181 | Application of Endoscopic Scissors Cutting ENBD Tube in the Treatment of Malignant Hilar…(ENBD) | N/A | withdrawn | Nov 27, 2017 | Changhai Hospital | Failure to recruit patients | Enrollment / accrual |
| NCT03998033 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma(ET-109) | Phase 1 | terminated | Jun 25, 2019 | Eureka Therapeutics Inc. | Reallocation of resources to new HCC study. | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 14, 2023source: clinicaltrials